Alliance Pharma (APH)

 

APH Share PerformanceMore

52 week high63.00 05/12/17
52 week low41.79 23/12/16
52 week change 15.38 (33.33%)
4 week volume9,063,086 18/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - finnCap issues a broker note on Alliance Pharma PLC

finnCap today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and raised its price target to 70p ...

Broker Forecast - Numis issues a broker note on Alliance Pharma PLC

Numis today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and set its price target at 71p.

Alliance to acquire rights to Vamousse

Alliance Pharma's wholly owned subsidiary, Alliance Pharmaceuticals Limited, has agreed to acquire the worldwide rights...

Tender Offer to Shareholders and Notice of Meeting

RNS Number: 2190Y TyraTech, Inc. 04 December 2017 TYRATECH, INC. ("TyraTech" or the "Company") PROPOSED SALE OF VAMOUSSE FOR INITIAL CONSIDERATION OF $13 MILLION IN CASH NEW STRATEGIC FOCUS ON ANIMAL HEALTH Tender Offer to Shareholders and Notice of Special Meeting of Shareholders TyraTech Inc. (AIM: TYR, an...

Proposed acquisition of Vamousse

RNS Number: 2201Y Alliance Pharma PLC 04 December 2017 For immediate release 4 December 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Group") Proposed acquisition of Vamousse Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, has entered into an...

Broker Forecast - Numis issues a broker note on Alliance Pharma PLC

Numis today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and set its price target at 66p.

Alliance acquires Ametop rights for $7.5m

Alliance Pharma's wholly-owned subsidiary, Alliance Pharmaceuticals, has acquired all of the rights to Ametop from glob...

Acquisition of AmetopT

RNS Number: 1025Y Alliance Pharma PLC 01 December 2017 For immediate release 1 December 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Group") Acquisition of Ametop Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, has acquired all of the rights t...

Fundamental DataMore

P/E ratio15.974
EPS3.85
Dividend yield1.967 %

Latest discussion posts More

  • Re: Another good move

    Actually invested in this and Tyratech and think this is a good move for both. Vamousse is a strong differentiated product in this segment, with USPs that will appeal to ...
    4-Dec-2017
    tonkatruck
  • Re: Another good move

    Agreed, Seems a reasonable acquisition, hopefully our reach can boost sales. Have to admit I had never heard of Vamousse, but having never having head lice (as far as I know) ...
    4-Dec-2017
    NoQuestionMarks
  • Another good move

    See RNS today. Another good move, this acquisition will also be immediately earnings enhancing. Management on the ball here. IMHO, ws
    4-Dec-2017
    winningstreak

Users' HoldingsMore

Users who hold Alliance Pharma also hold..
ID:ISIN:GB00BJFL1R44100%
CITY MERCH.HIGH100%
3I GRP.100%
RENISHAW100%
XP POWER100%

Codes & Symbols

ISINGB0031030819
SymbolsAPH, LSE:APH, APH.L, APH:LN, LON:APH, XLON:APH

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account